Arca
Skip to content

Hereditary angioedema

Drug research and approvals for hereditary angioedema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 19 studies of hereditary angioedema are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 16 approved and 4 open orphan designations naming it, and the EU has 9 authorised medicines for it.

  • Recruiting worldwide: 19
  • Trials authorized in Canada: 41
  • FDA orphan approvals: 16
  • EU medicines: 9

Recruiting Now

Newest start dates first, of 19 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 41; search them all in Canada trials
Apr 7, 2026A phase 3 extension study of sirna targeting of prekallikrein with adx-324 in participants with hereditary angioedemaONVUZOSIRAN (ADX-324)ADARX PHARMACEUTICALS, INC.Pending
Dec 3, 2025An open-label study of donidalorsen in pediatric patients age 2 to less than 12 years old with hereditary angioedemaDONIDALORSEN (ISIS721744)Ionis PharmaceuticalsClosed
Sep 26, 2025Phase 3 trial to evaluate the long-term safety and efficacy of navenibart in participants with hereditary angioedema – orbit-expanseNAVENIBARTASTRIA THERAPEUTICS, INC.Ongoing
Sep 25, 2025A phase 3, randomized, double-blind, placebo controlled study of sirna targeting of prekallikrein with adx-324 in participants with hereditary angioedemaONVUZOSIRAN (ADX-324)ADARX PHARMACEUTICALS, INC.Ongoing
Jul 29, 2025An open-label study to provide berotralstat access to subjects with type i and ii hereditary angioedema who were previously enrolled in berotralstat studiesBEROTRALSTAT (BCX7353)BioCryst PharmaceuticalsClosed
Jul 10, 2025Post study access of csl312 (garadacimab) for the routine prevention of hereditary angioedema (hae) attacks in adult and adolescent participants (¿ 12 years…CSL312 (GARADACIMAB)CSLPending
May 13, 2025Post study access of csl312 (garadacimab) for the routine prevention of hae attacks in pediatric participants (2-11 years old) with hereditary angioedema (hae)…GARADACIMAB (CSL312)CSLOngoing
Mar 19, 2025Phase 3, multicenter, randomized, double-blind, placebo controlled trial to evaluate the efficacy and safety of navenibart in participants with hereditary…NAVENIBART (STAR-0215)ASTRIA THERAPEUTICS, INC.Ongoing
Jan 14, 2025A phase 4 open-label study to evaluate the safety after switching to csl312 (garadacimab) from current prophylactic hae treatment in subjects with hae ¿ 12…CSL312 (GARADACIMAB) (FACTOR XIIA ANTAGONIST MONOCLONAL ANTIBODY)CSLClosed
Oct 31, 2024Haelo: a phase 3, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ntla-2002 in participants with…NTLA-2002INTELLIA THERAPEUTICS, INC.Ongoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 20
Dec 11, 2025Orladeyoprophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and olderBioCryst Pharmaceuticals, Inc.Approved
Aug 21, 2025Dawnzeraprophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and olderIonis PharmaceuticalsApproved
Jul 3, 2025Ekterlytreatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and olderKalVista Pharmaceuticals LtdApproved
Jun 16, 2025Andembryprophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and olderCSL BehringApproved
Feb 3, 2023Takhzyroprophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and olderTakeda Pharmaceuticals U.S.A., Inc.Approved
Dec 3, 2020ORLADEYO™prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and olderBioCryst Pharmaceuticals, Inc.Approved
Sep 24, 2020HaegardaHAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary…CSL Behring LLCApproved
Aug 23, 2018TakhzyroProphylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and olderTakeda Pharmaceuticals U.S.A., Inc.Approved
Jun 20, 2018CinryzeCINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric…Takeda Development Center Americas, Inc.Approved
Jun 22, 2017HaegardaFor routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.CSL Behring LLCApproved
Jul 16, 2014RUCONESTTreatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.Pharming Group N.V.Approved
Mar 28, 2014KalbitorTreatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and olderTakeda Pharmaceuticals U.S.A., Inc.Approved
Aug 25, 2011FirazyrTreatment of acute attacks of hereditary angioedema in adults 18 years of age and olderTakeda Development Center Americas, Inc.Approved
Dec 1, 2009KalbitorTreatment of acute attacks of hereditary angioedema in patients 16 years of age and olderTakeda Pharmaceuticals U.S.A., Inc.Approved
Oct 8, 2009BerinertTreatment of acute attacks of hereditary angioedema.CSL Behring LLCApproved

Medicines Authorised in the EU

Newest first
Jan 19, 2026DawnzeradonidalorsenOtsuka Pharmaceutical Netherlands B.V.EMA ↗
Sep 17, 2025Ekterlysebetralstat · orphanKalvista Pharmaceuticals (Ireland) LimitedEMA ↗
Feb 10, 2025AndembrygaradacimabCSL Behring GmbHEMA ↗
Jul 16, 2021Icatibant Accordicatibant · genericAccord Healthcare S.L.U.EMA ↗
Apr 30, 2021OrladeyoberotralstatNeopharmed Gentili Ireland LimitedEMA ↗
Nov 22, 2018Takhzyrolanadelumab · orphanTakeda Pharmaceuticals International AG Ireland BranchEMA ↗
Jun 15, 2011CinryzeC1 inhibitor (human)Takeda Manufacturing Austria AGEMA ↗
Oct 28, 2010Ruconestconestat alfaPharming Group N.V.EMA ↗
Jul 11, 2008FirazyricatibantTakeda Pharmaceuticals International AGEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.